Testing a new treatment for systemic sclerosis skin hardening
Part of Skin clinical trials.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have systemic sclerosis diagnosed by standard criteria, specifically the diffuse (widespread) type affecting large areas of skin
- Your systemic sclerosis symptoms must have started within the last 5 years
- If you take immune-suppressing medications, you must have been on the same stable dose for at least 1 month, and not started any new ones in the past 2 months
- You cannot have other autoimmune diseases besides systemic sclerosis (such as lupus or dermatomyositis)
- You cannot be pregnant or breastfeeding
- You must not have active cancer, untreated infections (including HIV, hepatitis B or C, or tuberculosis), or severe uncontrolled medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This research study uses special lab-grown stem cells to understand how systemic sclerosis (a disease that hardens skin and organs) develops and progresses. By studying cells from patients with different types of systemic sclerosis and healthy relatives, researchers hope to find new ways to treat or prevent the disease.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.